Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects with Type 2 Diabetes

Study identifier:2993-119

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects with Type 2 Diabetes Mellitus

Medical condition

Diabetes Mellitus, Type 2

Phase

Phase 3

Healthy volunteers

No

Study drug

exenatide

Sex

All

Actual Enrollment

456

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Nov 2002
Primary Completion Date: 01 Sept 2006
Study Completion Date: 01 Sept 2006

Study design

Allocation: N/A
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

N/A

Inclusion and exclusion criteria